Context matters: the hen or egg problem in Ewing's sarcoma
- PMID: 15826833
- DOI: 10.1016/j.semcancer.2005.01.004
Context matters: the hen or egg problem in Ewing's sarcoma
Abstract
Ewing's sarcoma and related tumors (ESFT) are characterized by rearrangements of EWS with ets family genes. While detection of these gene fusions greatly facilitated diagnosis, it has not provided any clues about the tissue of origin. Immunological and gene expression profiling studies favour a neuroectodermal histogenesis. These investigations did not appreciate the impact of EWS-ets proteins on the tumor phenotype. Introduction of EWS-ets into different cellular models resulted in diverse outcomes ranging from the induction of cell cycle arrest or apoptosis to transformation and tumorigenicity, and from blocked differentiation to trans-differentiation. Thus, the molecular signature of EWS-ets proteins depends on the cell type. The hen or egg problem in ESFT, therefore, is whether ESFT reflect the phenotype of the tumor stem cell that is blocked in differentiation by the activity of the EWS-ets gene fusion or if the oncogene imposes an incomplete differentiation program on a pluripotent precursor cell. This article addresses the problem by considering the tissue distribution of FLI1 and ERG expression and by reviewing evidence for combinatorial control of EWS-ets activity.
Similar articles
-
Biphenotypic sarcomas with myogenic and neural differentiation express the Ewing's sarcoma EWS/FLI1 fusion gene.Cancer Res. 1995 Mar 15;55(6):1385-92. Cancer Res. 1995. PMID: 7882340
-
EWS-FLI1 fusion protein up-regulates critical genes in neural crest development and is responsible for the observed phenotype of Ewing's family of tumors.Cancer Res. 2005 Jun 1;65(11):4633-44. doi: 10.1158/0008-5472.CAN-04-2857. Cancer Res. 2005. PMID: 15930281
-
EWS/ETS proteins promote expression and regulate function of the homeodomain transcription factor BRN3A.Oncogene. 2010 May 27;29(21):3134-45. doi: 10.1038/onc.2010.72. Epub 2010 Mar 29. Oncogene. 2010. PMID: 20348952
-
Biology of EWS/ETS fusions in Ewing's family tumors.Oncogene. 2001 Sep 10;20(40):5747-54. doi: 10.1038/sj.onc.1204598. Oncogene. 2001. PMID: 11607824 Review.
-
Advances in Ewing's sarcoma research: where are we now and what lies ahead?Cancer Res. 2009 Sep 15;69(18):7140-50. doi: 10.1158/0008-5472.CAN-08-4041. Epub 2009 Sep 8. Cancer Res. 2009. PMID: 19738075 Review.
Cited by
-
Recapitulating the Size and Cargo of Tumor Exosomes in a Tissue-Engineered Model.Theranostics. 2016 May 21;6(8):1119-30. doi: 10.7150/thno.13944. eCollection 2016. Theranostics. 2016. PMID: 27279906 Free PMC article.
-
Recent advances in the molecular pathogenesis of Ewing's sarcoma.Oncogene. 2010 Aug 12;29(32):4504-16. doi: 10.1038/onc.2010.205. Epub 2010 Jun 14. Oncogene. 2010. PMID: 20543858 Free PMC article. Review.
-
Extracellular Vesicles in Reprogramming of the Ewing Sarcoma Tumor Microenvironment.Front Cell Dev Biol. 2021 Sep 17;9:726205. doi: 10.3389/fcell.2021.726205. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 34604225 Free PMC article. Review.
-
Oncogenic partnerships: EWS-FLI1 protein interactions initiate key pathways of Ewing's sarcoma.Clin Cancer Res. 2010 Aug 15;16(16):4077-83. doi: 10.1158/1078-0432.CCR-09-2261. Epub 2010 Jun 14. Clin Cancer Res. 2010. PMID: 20547696 Free PMC article. Review.
-
Imatinib revives the therapeutic potential of metformin on ewing sarcoma by attenuating tumor hypoxic response and inhibiting convergent signaling pathways.Cancer Lett. 2020 Jan 28;469:195-206. doi: 10.1016/j.canlet.2019.10.034. Epub 2019 Oct 28. Cancer Lett. 2020. PMID: 31672491 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources